Biosimilars cost savings: a valuable impact on healthcare costs

Biosimilars are expected to have a robust impact on lowering healthcare costs

  • Biosimilars are expected to save the EU up to $44B in healthcare costs by 2020.1
  • Over the next 5–10 years in the US, it is estimated that biosimilars can save the healthcare system approximately $150B.2

The value of biosimilars in the marketplace

  • Biosimilars offer the opportunity for system-wide cost savings3
  • The introduction of biosimilars can provide headroom for greater investment in innovator products3
  • Biosimilars can provide more treatment options to patients with serious illnesses3

The value of biosimilars

Related articles and links:

References: 1. Inside Sources. Europe demonstrates benefits of a strong biosimilars marketplace. www.insidesources.com/europe-demonstrates-benefits-strong-biosimilars-marketplace/. Accessed October 29, 2019. 2. The Center For Biosimilars. Biosimilars market is ripe for cost savings. www.centerforbiosimilars.com/contributor/chad-pettit/2019/06/biosimilars-market-is-ripe-for-cost-savings. Accessed October 29, 2019. 3. The Biosimilars Council. Biosimilars in the United States. http://biosimilarscouncil.org/wp-content/uploads/2019/03/Biosimilars-Council-Patient-Access-Study.pdf. Accessed October 29, 2019.